Christopher Doe

Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors

Krista Goodman, Haifeng Cui, Sarah E. Dowdell et al. · Journal of Medicinal Chemistry · 2006 · 154 citations · Full text

Indazole Substitution, Medicinal Chemistry, Oral Bioavailability +11

Synthetic LXR agonists increase LDL in CETP species

Pieter H.E. Groot, John Yates, Claire J. Stocker et al. · Journal of Lipid Research · 2005 · 116 citations · Full text

Effects of p38 MAPK Inhibitor on Angiotensin II-Dependent Hypertension, Organ Damage, and Superoxide Anion Production

Weike Bao, David J. Behm, Sandhya S. Nerurkar et al. · Journal of Cardiovascular Pharmacology · 2007 · 98 citations

Hypertension, Cardiovascular Pharmacology, P38 Mapk +17

Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases

Clark A. Sehon, Gren Z. Wang, Andrew Q. Viet et al. · Journal of Medicinal Chemistry · 2008 · 72 citations · Full text

Medicinal Chemistry, Potential Therapeutic Agents, Biochemistry +15

Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity

Robert A. Stavenger, Haifeng Cui, Sarah E. Dowdell et al. · Journal of Medicinal Chemistry · 2006 · 71 citations · Full text

Drug Target, Bioorganic Chemistry, Pharmacotherapy +18